Background: A recent study found that US women aged 45–54 years in 1999–2004 were twice as likely as men to report previous stroke. The aim of this study was to evaluate the validity of this finding by assessing the sex-specific midlife stroke prevalence in the most recent nationally representative, cross-sectional sample of US individuals. Methods: Sex-specific stroke prevalence, sex-specific vascular risk factor prevalence and sex-specific independent predictors of stroke were assessed among 35- to 64-year olds who participated in the National Health and Nutrition Examination Surveys in 2005–2006 (n = 2,274). Results: Women aged 35–64 years were almost 3 times more likely than men to report prior stroke (2.90 vs. 1.07%; p < 0.001). This disparity was driven by the 45- to 54-year age group, where women had thrice the odds of prior stroke compared with men (OR 3.12, 95% CI 1.30–7.50). Among 45- to 54-year olds, men were more likely than women to have a history of smoking, elevated homocysteine and elevated triglyceride levels, but less likely to be abdominally obese (p < 0.001). Independent stroke risk factors among women aged 35–64 years were a homocysteine level >8.5 µmol/l (OR 6.19, 95% CI 2.57–14.93), a history of myocardial infarction (OR 5.35, 95% CI 1.09–26.27) and diabetes mellitus (OR 6.63, 95% CI 2.47–17.81). Conclusion: The midlife sex disparity in US stroke prevalence persists. Greater emphasis on prompt recognition and treatment of cardiovascular risk factors among young and middle-aged women may ameliorate this worrisome trend.

Bushnell CD, Hurn P, Colton C, Miller VM, del Zoppo G, Elkind MS, Stern B, Herrington D, Ford-Lynch G, Gorelick P, James A, Brown CM, Choi E, Bray P, Newby LK, Goldstein LB, Simpkins J: Advancing the study of stroke in women: summary and recommendations for future research from an NINDS-sponsored multidisciplinary working group. Stroke 2006;37:2387–2399.
Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Stafford R, Thom T, Wasserthiel-Smoller S, Wong ND, Wylie-Rosett J: Heart disease and stroke statistics – 2010 update: a report from the American Heart Association. Circulation 2010;121:e46–e215.
Reeves MJ, Bushnell CD, Howard G, Gargano JW, Duncan PW, Lynch G, Khatiwoda A, Lisabeth L: Sex differences in stroke: epidemiology, clinical presentation, medical care, and outcomes. Lancet Neurol 2008;7:915–926.
Di Carlo A, Lamassa M, Baldereschi M, Pracucci G, Basile AM, Wolfe CD, Giroud M, Rudd A, Ghetti A, Inzitari D: Sex differences in the clinical presentation, resource use, and 3-month outcome of acute stroke in Europe: data from a multicenter multinational hospital-based registry. Stroke 2003;34:1114–1119.
Kapral MK, Fang J, Hill MD, Silver F, Richards J, Jaigobin C, Cheung AM: Sex differences in stroke care and outcomes: results from the registry of the Canadian stroke network. Stroke 2005;36:809–814.
Gargano JW, Wehner S, Reeves M: Sex differences in acute stroke care in a statewide stroke registry. Stroke 2008;39:24–29.
Glader EL, Stegmayr B, Norrving B, Terent A, Hulter-Asberg K, Wester PO, Asplund K: Sex differences in management and outcome after stroke: a Swedish national perspective. Stroke 2003;34:1970–1975.
Roquer J, Campello AR, Gomis M: Sex differences in first-ever acute stroke. Stroke 2003;34:1581–1585.
Niewada M, Kobayashi A, Sandercock PA, Kaminski B, Czlonkowska A: Influence of gender on baseline features and clinical outcomes among 17,370 patients with confirmed ischaemic stroke in the International Stroke Trial. Neuroepidemiology 2005;24:123–128.
Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE: A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293–1304.
Centers for Disease Control and Prevention. Prevalence of stroke: United States, 2005. MMWR Morb Mortal Wkly Rep 2007;56:469–474.
Rosamond WD, Folsom AR, Chambless LE, Wang CH, McGovern PG, Howard G, Copper LS, Shahar E: Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke 1999;30:736–743.
Towfighi A, Saver JL, Engelhardt R, Ovbiagele B: A midlife stroke surge among women in the United States. Neurology 2007;69:1898–1904.
Towfighi A, Zheng L, Ovbiagele B: Weight of the obesity epidemic: rising stroke rates among middle-aged women in the United States. Stroke 2010;41:1371–1375.
Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS): National Health and Nutrition Examination Survey questionnaire, examination protocol, and laboratory protocols. Hyattsville, Department of Health and Human Services, 2005–2006. (accessed August 20, 2009).
Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials. Am Heart J 2006;151:282–287.
Jacques PF, Selhub J, Bostom AG, Wilson PW, Rosenberg IH: The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 1999;340:1449–1454.
McCully KS: Homocysteine, vitamins, and vascular disease prevention. Am J Clin Nutr 2007;86:1563S–1568S.
Giles WH, Croft JB, Greenlund KJ, Ford ES, Kittner SJ: Total homocyst(e)ine concentration and the likelihood of nonfatal stroke: results from the third National Health and Nutrition Examination Survey, 1988–1994. Stroke 1998;29:2473–2477.
Hankey GJ, Jamrozik K, Broadhurst RJ, Forbes S, Burvill PW, Anderson CS, Stewart-Wynne EG: Five-year survival after first-ever stroke and related prognostic factors in the Perth Community Stroke Study. Stroke 2000;31:2080–2086.
Hollander M, Koudstaal PJ, Bots ML, Grobbee DE, Hofman A, Breteler MM: Incidence, risk, and case fatality of first ever stroke in the elderly population. The Rotterdam study. J Neurol Neurosurg Psychiatry 2003;74:317–321.
US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics (NCHS): Health, United States, 2008. (accessed August 20, 2009).
Kissela B, Schneider A, Kleindorfer D, Khoury J, Miller R, Alwell K, Woo D, Szaflarski J, Gebel J, Moomaw C, Pancioli A, Jauch E, Shukla R, Broderick J: Stroke in a biracial population: the excess burden of stroke among blacks. Stroke 2004;35:426–431.
Brown RD, Whisnant JP, Sicks JD, O’Fallon WM, Wiebers DO: Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989. Stroke 1996;27:373–380.
Medin J, Nordlund A, Ekberg K: Increasing stroke incidence in Sweden between 1989 and 2000 among persons aged 30 to 65 years: evidence from the Swedish hospital discharge register. Stroke 2004;35:1047–1051.
Petrea RE, Beiser AS, Seshadri S, Kelly-Hayes M, Kase CS, Wolf PA: Gender differences in stroke incidence and poststroke disability in the Framingham Heart Study. Stroke 2009;40:1032–1037.
Lu M, Ye W, Adami HO, Weiderpass E: Prospective study of body size and risk for stroke amongst women below age 60. J Intern Med 2006;260:442–450.
Sowers M, Zheng H, Tomey K, Karvonen-Gutierrez C, Jannausch M, Li X, Yosef M, Symons J: Changes in body composition in women over six years at mid-life: ovarian and chronological aging. J Clin Endocrinol Metab 2007;92:895–901.
Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM: Prevalence of overweight and obesity in the United States, 1999–2004. JAMA 2006;295:1549–1555.
Towfighi A, Zheng L, Ovbiagele B: Sex-specific trends in midlife coronary heart disease risk and prevalence. Arch Intern Med 2009;169:1762–1766.
Almdal T, Scharling H, Jensen JS, Vestergaard H: The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med 2004;164:1422–1426.
Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002;288:2015–2022.
Hankey GJ, Algra A, Chen C, Wong MC, Cheung R, Wong L, Divjak I, Ferro J, de Freitas G, Gommans J, Groppa S, Hill M, Spence D, Lees K, Lisheng L, Navarro J, Ranawaka U, Ricci S, Schmidt R, Slivka A, Tan K, Tsiskaridze A, Uddin W, Vanhooren G, Xavier D, Armitage J, Hobbs M, Le M, Sudlow C, Wheatley K, Yi Q, Bulder M, Eikelboom JW, Hankey GJ, Ho WK, Jamrozik K, Klijn K, Koedam E, Langton P, Nijboer E, Tuch P, Pizzi J, Tang M, Antenucci M, Chew Y, Chinnery D, Cockayne C, Loh K, McMullin L, Smith F, Schmidt R, Chen C, Wong MC, de Freitas G, Hankey GJ, Loh K, Song S: Vitatops, the vitamins to prevent stroke trial: rationale and design of a randomised trial of B-vitamin therapy in patients with recent transient ischaemic attack or stroke (NCT00097669) (ISRCTN74743444). Int J Stroke 2007;2:144–150.
Engstad T, Bonaa KH, Viitanen M: Validity of self-reported stroke: the Tromso Study. Stroke 2000;31:1602–1607.
O’Mahony PG, Dobson R, Rodgers H, James OF, Thomson RG: Validation of a population screening questionnaire to assess prevalence of stroke. Stroke 1995;26:1334–1337.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.